Skip To Main Content
Barry Rosenstein on Muck Rack

Barry Rosenstein

As seen in: Nature, USA Today, Nasdaq, Barchart, Future Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barry

Contact Barry, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Long-term fatigue dimensions in the Multidimensional Fatigue Inventory (MFI) up to five years after radiotherapy and their trajectories in men diagnosed with non-metastatic prostate cancer in the international REQUITE study

|
By Philipp Heumann, juan rosas, Miguel E. Aguado-Barrera, David Azria, Axel Benner, Erik Briers, Ananya Choudhury, Antonio Gomez-Caamano, Rudolf Kaaks, Maarten Lambrecht, Tiziana Rancati, Barry Rosenstein, Dirk De Ruysscher, Martina Schmidt, Susanne Singer, Elena Sperk, Hilary Stobart, Ana Vega, Liv Veldeman, Adam Scott Webb, Catharine West, Jenny Chang-Claude, Christopher Talbot, Tim Rattay, Petra Seibold
| Nature Verified
Abstract Fatigue is a common, multidimensional symptom in cancer patients. Little is known about fatigue dimensions and their trajectories in prostate cancer (PCa). Using the Multidimensional Fatigue Inventory (MFI), 1097 men treated with radiotherapy for non-metastatic PCa (2014–2016) prospectively reported fatigue up to five years later. Prevalent fatigue was defined as scores ≥75th percentile in men aged ≥60 years in a German general population sample.
Open in Who Shared Issue with article?

Long-term fatigue based on the EORTC QLQ-C30 up to five years after radiotherapy and its trajectories in men diagnosed with non-metastatic prostate cancer in the international REQUITE study

|
By Philipp Heumann, juan rosas, Miguel E. Aguado-Barrera, David Azria, Axel Benner, Erik Briers, Ananya Choudhury, Antonio Gomez-Caamano, Rudolf Kaaks, Maarten Lambrecht, Tiziana Rancati, Barry Rosenstein, Dirk De Ruysscher, Martina Schmidt, Susanne Singer, Elena Sperk, Hilary Stobart, Ana Vega, Liv Veldeman, Tim Ward, Adam Scott Webb, Catharine West, Jenny Chang-Claude, Christopher Talbot, Tim Rattay, Petra Seibold
| Nature Verified
Abstract Fatigue is a common symptom in cancer patients associated with impaired quality of life (QoL). Little is known about long-term fatigue trajectories in prostate cancer (PCa) patients. Using the European Organisation for Research and Treatment of Cancer Quality of Life Group Core Questionnaire (EORTC QLQ-C30), 1758 men treated with radiotherapy (2014–2016) for non-metastatic PCa prospectively reported fatigue up to five years later.
Open in Who Shared Issue with article?

Great-West Lifeco's Preferred Shares, Series G About To Put More Money In Your Pocket

|
By Barry Rosenstein, BNK Invest
| Nasdaq Verified
On 9/1/26, Great-West Lifeco Inc's Non-Cumulative First Preferred Shares, Series G (TSX: GWO-PRG.TO) will trade ex-dividend, for its quarterly dividend of $0.325, payable on 9/29/26. As a percentage of GWO.PRG's recent share price of $23.76, this dividend works out to approximately 1.37%, so look for shares of GWO.PRG to trade 1.37% lower — all else being equal — when GWO.PRG shares open for trading on 9/1/26. On an annualized basis, the current yield is approximately 5.40%.
Open in Who Shared View Duplicates (8) Issue with article?
See all 175 articles